Pomerantz Law Firm Investigates Disc Medicine, Inc. for Potential Securities Fraud
Pomerantz LLP is investigating Disc Medicine, Inc. (IRON) for potential securities fraud following negative FDA developments related to its drug bitopertin. The stock price fell significantly after the FDA raised concerns about the drug's safety and efficacy, and again after the issuance of a Complete Response Letter. The firm is seeking to represent affected investors.
Tickers: $IRON
Topics: class action FDA review pharmaceuticals securities fraud stock price drop